Summary of Moderna's Extraordinary General Meeting Company Overview - **Company**: Moderna, Inc. (NasdaqGS:MRNA) - **Event**: 2025 Extraordinary General Meeting - **Date**: November 12, 2025 Key Points Meeting Structure and Procedures - The meeting was chaired by Noubar Afeyan, Chairman of the Board, with CEO Stéphane Bancel and Chief Legal Officer Shannon Klinger present [1][2] - A quorum was confirmed with proxies received for a majority of the shares outstanding as of the record date, September 30, 2025 [4] - Voting was conducted via proxy and virtual ballot, allowing shareholders to change their votes if desired [5] Proposals Discussed - **Proposal One**: Approval of a one-time stock option exchange program for non-executive committee employees - The Board of Directors unanimously recommended approval of this proposal [8] - **Proposal Two**: Approval to adjourn the special meeting to a later date if necessary - The Board also unanimously recommended approval of this proposal [8] Voting Results - Both proposals received the requisite number of votes in favor and were approved by shareholders [10] - Since Proposal One was approved, there was no need to adjourn the meeting [10] - Final voting results will be reported on Form 8-K to be filed with the SEC within four business days [11] Additional Notes - No shareholder questions relevant to the business of the special meeting were received in advance [12] - The meeting concluded with a note of appreciation for shareholder support [12]